What is it about?
This article explores how stakeholder engagement can help improve the development and introduction of rapid diagnostic tests for tuberculosis. Tuberculosis remains one of the world’s most serious infectious diseases, and early diagnosis is essential for starting treatment quickly, reducing transmission, and improving patient outcomes. However, even when new diagnostic technologies are available, they are not always easy to implement in real health systems. The article focuses on understanding the practical barriers that may limit the use of rapid tuberculosis tests. These barriers may include the cost of tests and equipment, limited laboratory capacity, supply and procurement challenges, the need for staff training, maintenance requirements, data reporting, and weak links between diagnosis and treatment. In some settings, geographic access, transportation of samples, and differences between central and peripheral health facilities can also affect whether patients benefit from rapid testing. By engaging with different stakeholders, including laboratory specialists, clinicians, tuberculosis program managers, researchers, and implementation partners, the study helps identify what is needed to make rapid diagnostic tools more useful and acceptable in practice. Stakeholder input is especially important because those working directly in tuberculosis services understand the real conditions, limitations, and needs of health systems. The findings of this article can support the development of diagnostic tools that are not only scientifically strong, but also affordable, practical, user-friendly, and suitable for countries with a high burden of tuberculosis. Overall, the article highlights that successful innovation in tuberculosis diagnostics requires both good technology and a clear understanding of real-world implementation challenges.
Featured Image
Photo by Julia Koblitz on Unsplash
Why is it important?
This article is important because rapid tuberculosis diagnosis can save lives, but new tests only make an impact when they can be used effectively in real health systems. Tuberculosis remains a major public health problem, and delays in diagnosis can lead to late treatment, continued transmission, more severe disease, and poorer outcomes for patients. Many diagnostic innovations are developed with strong scientific performance, but their practical use may be limited by cost, procurement systems, laboratory infrastructure, staff training, maintenance, sample transport, data reporting, and weak links between diagnosis and treatment. If these barriers are not understood early, even a good diagnostic tool may fail to reach the people who need it most. By engaging stakeholders, this article helps identify the real-world conditions that shape whether rapid tuberculosis tests can be successfully introduced and scaled up. Input from clinicians, laboratory specialists, tuberculosis program managers, researchers, and implementation partners helps ensure that diagnostic tools are not only accurate, but also practical, affordable, user-friendly, and suitable for different health system settings. This is especially important for countries with a high burden of tuberculosis, where faster and more accessible testing can improve case detection, support earlier treatment, reduce transmission, and strengthen national tuberculosis programs. The article therefore contributes to better planning, smarter diagnostic development, and more effective implementation of innovations in tuberculosis care.
Perspectives
This article provides important perspectives for the future development and implementation of rapid tuberculosis diagnostics. The findings show that new diagnostic tools should be designed not only for laboratory accuracy, but also for real-world use in different health system settings. Future rapid tuberculosis tests should be affordable, simple to operate, easy to maintain, and suitable for both central laboratories and peripheral health facilities. A key perspective is the need to involve stakeholders early in the development process. Clinicians, laboratory specialists, tuberculosis program managers, procurement experts, community representatives, and implementation partners can help developers understand what is practical, acceptable, and feasible in routine health services. Their input can guide product design, implementation planning, training needs, supply systems, data reporting, and linkage to treatment. The article also highlights the importance of adapting diagnostic innovations to the needs of high-burden countries. In these settings, rapid tests can have a major impact if they are accessible to patients, integrated into national tuberculosis programs, and supported by strong laboratory networks. Future research and implementation efforts should therefore focus on closing the gap between innovation and everyday practice. Overall, the article suggests that the future of tuberculosis diagnostics depends on combining strong science with practical implementation planning. By listening to stakeholders and addressing barriers early, new diagnostic tools can become more useful, scalable, and sustainable, helping countries improve tuberculosis detection, start treatment earlier, and reduce transmission.
Dr. Bakyt Bolotbekovich Myrzaliev
FHI 360
Read the Original
This page is a summary of: Stakeholder engagement to identify barriers to implementation and inform the development of point-of-care diagnostics for TB, IJTLD OPEN, April 2026, International Union Against Tuberculosis and Lung Disease,
DOI: 10.5588/ijtldopen.25.0680.
You can read the full text:
Contributors
The following have contributed to this page
